758 related articles for article (PubMed ID: 19200641)
21. Chemoprevention of prostate cancer: agents and study designs.
Thompson IM
J Urol; 2007 Sep; 178(3 Pt 2):S9-S13. PubMed ID: 17644117
[TBL] [Abstract][Full Text] [Related]
22. A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate.
Naslund MJ; Miner M
Clin Ther; 2007 Jan; 29(1):17-25. PubMed ID: 17379044
[TBL] [Abstract][Full Text] [Related]
23. Quantifying the impact of prostate volumes, number of biopsy cores and 5alpha-reductase inhibitor therapy on the probability of prostate cancer detection using mathematical modeling.
Serfling R; Shulman M; Thompson GL; Xiao Z; Benaim E; Roehrborn CG; Rittmaster R
J Urol; 2007 Jun; 177(6):2352-6. PubMed ID: 17509357
[TBL] [Abstract][Full Text] [Related]
24. Do the benefits of finasteride outweigh the risks in the prostate cancer prevention trial?
Grover S; Lowensteyn I; Hajek D; Trachtenberg J; Coupal L; Marchand S
J Urol; 2006 Mar; 175(3 Pt 1):934-8; discussion 938. PubMed ID: 16469585
[TBL] [Abstract][Full Text] [Related]
25. [Nutrition and pharmacological treatment for prevention of prostate cancer].
Segev Y; Nativ O
Harefuah; 2006 Jan; 145(1):47-51, 76-7. PubMed ID: 16450727
[TBL] [Abstract][Full Text] [Related]
26. Delay in the progression of low-risk prostate cancer: rationale and design of the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trial.
Fleshner N; Gomella LG; Cookson MS; Finelli A; Evans A; Taneja SS; Lucia MS; Wolford E; Somerville MC; Rittmaster R;
Contemp Clin Trials; 2007 Nov; 28(6):763-9. PubMed ID: 17573244
[TBL] [Abstract][Full Text] [Related]
27. Type 1 and type 2 5alpha-reductase expression in the development and progression of prostate cancer.
Thomas LN; Douglas RC; Lazier CB; Too CK; Rittmaster RS; Tindall DJ
Eur Urol; 2008 Feb; 53(2):244-52. PubMed ID: 18006217
[TBL] [Abstract][Full Text] [Related]
28. Finasteride as a chemopreventive agent in prostate cancer: impact of the PCPT on urologic practice.
Goetzl MA; Holzbeierlein JM
Nat Clin Pract Urol; 2006 Aug; 3(8):422-9. PubMed ID: 16902518
[TBL] [Abstract][Full Text] [Related]
29. Chemoprevention of prostate cancer.
Thompson IM; Tangen CM; Goodman PJ; Lucia MS; Klein EA
J Urol; 2009 Aug; 182(2):499-507; discussion 508. PubMed ID: 19524966
[TBL] [Abstract][Full Text] [Related]
30. Prostate cancer prevention and finasteride.
D'Amico AV; Barry MJ
J Urol; 2006 Nov; 176(5):2010-2; discussion 2012-3. PubMed ID: 17070238
[TBL] [Abstract][Full Text] [Related]
31. Screening for prostate cancer.
Brawley OW; Ankerst DP; Thompson IM
CA Cancer J Clin; 2009; 59(4):264-73. PubMed ID: 19564245
[TBL] [Abstract][Full Text] [Related]
32. The effects of 5alpha-reductase inhibitors on the natural history, detection and grading of prostate cancer: current state of knowledge.
Andriole G; Bostwick D; Civantos F; Epstein J; Lucia MS; McConnell J; Roehrborn CG
J Urol; 2005 Dec; 174(6):2098-104. PubMed ID: 16280736
[TBL] [Abstract][Full Text] [Related]
33. Assessing benefit and risk in the prevention of prostate cancer: the prostate cancer prevention trial revisited.
Klein EA; Tangen CM; Goodman PJ; Lippman SM; Thompson IM
J Clin Oncol; 2005 Oct; 23(30):7460-6. PubMed ID: 16157937
[TBL] [Abstract][Full Text] [Related]
34. Detection bias due to the effect of finasteride on prostate volume: a modeling approach for analysis of the Prostate Cancer Prevention Trial.
Cohen YC; Liu KS; Heyden NL; Carides AD; Anderson KM; Daifotis AG; Gann PH
J Natl Cancer Inst; 2007 Sep; 99(18):1366-74. PubMed ID: 17848668
[TBL] [Abstract][Full Text] [Related]
35. 5alpha-Reductase inhibitor treatment of prostatic diseases: background and practical implications.
Dörsam J; Altwein J
Prostate Cancer Prostatic Dis; 2009; 12(2):130-6. PubMed ID: 19030020
[TBL] [Abstract][Full Text] [Related]
36. Prevention of prostate cancer with finasteride.
Barzell WE
N Engl J Med; 2003 Oct; 349(16):1569-72; author reply 1569-72. PubMed ID: 14562803
[No Abstract] [Full Text] [Related]
37. Finasteride decreases the risk of prostatic intraepithelial neoplasia.
Thompson IM; Lucia MS; Redman MW; Darke A; La Rosa FG; Parnes HL; Lippman SM; Coltman CA
J Urol; 2007 Jul; 178(1):107-9; discussion 110. PubMed ID: 17499284
[TBL] [Abstract][Full Text] [Related]
38. Prevention of prostate cancer with finasteride.
Ross RK; Skinner E; Cote RJ
N Engl J Med; 2003 Oct; 349(16):1569-72; author reply 1569-72. PubMed ID: 14562807
[No Abstract] [Full Text] [Related]
39. Looking back at PCPT: looking forward to new paradigms in prostate cancer screening and prevention.
Canby-Hagino E; Hernandez J; Brand TC; Thompson I
Eur Urol; 2007 Jan; 51(1):27-33. PubMed ID: 17030406
[TBL] [Abstract][Full Text] [Related]
40. An update on chemoprevention strategies in prostate cancer for 2006.
Neill MG; Fleshner NE
Curr Opin Urol; 2006 May; 16(3):132-7. PubMed ID: 16679848
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
